StockNews.AI
AZTR
StockNews.AI
160 days

Azitra to Present at Microbiome Times Partnering Forum

1. Azitra's COO will present on ATR-12 at a Brussels forum in March 2025. 2. ATR-12 targets Netherton syndrome, a rare skin disease without current treatments. 3. Azitra also develops ATR-04 for EGFR inhibitor-associated rashes, now in clinical trials. 4. The company holds FDA Fast Track designation for ATR-04, aiding its commercialization strategy. 5. Management will seek investor partnerships during the conference to bolster funding.

8m saved
Insight
Article

FAQ

Why Bullish?

The upcoming presentation could boost investor confidence in Azitra's unique therapies. Past successes of biopharma companies in similar situations often led to positive price movements.

How important is it?

The article indicates strategic engagement with investors, crucial for funding and growth. It highlights ongoing clinical trials that may influence future valuation significantly.

Why Short Term?

The presentation is imminent, potentially leading to swift changes in stock perception. Historical examples show immediate stock responses to positive news from major events.

Related Companies

EGHTALNATSRX
, /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that Chief Operating Officer, Travis Whitfill, Ph.D., MPH will present at the Microbiome Times Partnering Forum being held in Brussels, Belgium, March 18-19, 2025. Details of the presentation are as follows: Event: Microbiome Times Partnering Forum Location: Dome Eventhall, Brussels, Belgium Date/Time: Wednesday, March 19th, 4:25-4:35pm CET Title: Engineered S. Epidermidis for Treating Skin Diseases: Early Clinical Experience in Netherton Syndrome With ATR-12 Presenter: Travis Whitfill, Chief Operating Officer Registration: https://www.microbiomeforum.com/register During the conference, members of Azitra's management team will conduct one-on-one meetings with registered investors and potential partners, showcasing the Azitra's business and clinical development strategy, recent corporate achievements, and anticipated milestones. About Azitra, Inc. Azitra, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology. The Company's lead product, ATR-12, is an engineered strain of S. epidermidis designed to treat Netherton syndrome, a rare, chronic skin disease with no approved treatment options. Netherton syndrome is often fatal in infancy with those living beyond a year having profound lifelong challenges. ATR-12 is being evaluated in a Phase 1b clinical trial in adult Netherton syndrome patients. ATR-04, Azitra's next most advanced product, is being developed for the treatment of EGFR inhibitor ("EGFRi") associated rash. Azitra has received Fast Track designation from the FDA for EGFRi associated rash, which impacts approximately 150,000 people in the U.S. Azitra has an open IND for a Phase 1/2 clinical trial with ATR-04 in patients with EGFRi associated rash. ATR-12 and ATR-04 were developed from Azitra's proprietary platform of engineered proteins and topical live biotherapeutic products that includes a microbial library comprised of approximately 1,500 bacterial strains. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen the library of strains for drug like molecules. For more information, please visit https://azitrainc.com. Forward-Looking Statements: This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements, the expected timing of the presentation of data from the Phase 1b study of ATR-12, and statements about our clinical and pre-clinical programs, and corporate and clinical/pre-clinical strategies. Any forward-looking statements in this press release are based on current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, that we may fail to successfully complete our Phase 1b trial for ATR-12; we may experience delays in the initiation of our Phase 1/2 trial for ATR-04; our product candidates may not be effective; there may be delays in regulatory approval or changes in regulatory framework that are out of our control; our estimation of addressable markets of our product candidates may be inaccurate; we may fail to timely raise additional required funding; more efficient competitors or more effective competing treatment may emerge; we may be involved in disputes surrounding the use of our intellectual property crucial to our success; we may not be able to attract and retain key employees and qualified personnel; earlier study results may not be predictive of later stage study outcomes; and we are dependent on third-parties for some or all aspects of our product manufacturing, research and preclinical and clinical testing. Additional risks concerning Azitra's programs and operations are described in our Annual Report on Form 10-K filed with the SEC on February 24, 2025 and subsequent filings we make with the SEC. Azitra explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Contact: Norman StaskeyChief Financial Officer[email protected] Tiberend Strategic Advisors, Inc.Jon Nugent205-566-3026[email protected] SOURCE Azitra, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News